Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab

Figures & data

Table 1 Patient demographics and characteristics

Contents	Treatment-naïve group	Switching group
Age, mean (SD), years	66.4 (11.0)	72.0 (8.4)
Sex, male/female	11/16	10/17
Number of IVR	–	2.9 (2.0)
Visual acuity logMAR, Snellen	0.49 (0.38), 20/60	0.48 (0.29), 20/60
Hypertension, +/−	11/16	14/13
Diabetes, +/−	4/23	4/23
CMT, µm	559.0 (161.9)	511.6 (152.5)
CME, +/−	17/10	17/10
SRF, +/−	10/17	5/22
ERM, +/−	1/26	5/22

Note: Both groups comprised 27 eyes of 27 patients.

Abbreviations: SD, standard deviation; IVR, intravitreal ranibizumab; logMAR, logarithm of the minimum angle of resolution; CMT, central macular thickness; CME, cystoid macula edema; SRF, subretinal fluid; ERM, epiretinal membrane.

Figure 1 Improvement of BCVA and CMT from preinjection in the treatment-naïve group. There was a significant improvement at 1 week and 1 month post-IVA for both the BCVA and CMT.

Abbreviations: BCVA, best-corrected visual acuity; CMT, central macular thickness; IVA, intravitreal aflibercept.

Figure 2 Improvement of BCVA and CMT from preswitch in the switching group. There was a significant improvement in BCVA at 1 month post-IVA and a significant improvement in CMT at 1 week and 1 month post-IVA.

Abbreviations: BCVA, best-corrected visual acuity; CMT, central macular thickness; IVA, intravitreal aflibercept.

Table 2 Preswitching factors associated with visual acuity at 1 month post-IVA

Variable factors	Visual acuity (logMAR)			Logistic regression analysis
	≤0.15	>0.15	P-value	Crude odds ratio	95% CI	P-value
Age, mean (SD), years	66.0 (8.5)	75.1 (6.7)	0.015	1.201	1.027–1.403	0.02
Sex, male/female	5/4	5/13	0.16
Duration from onset	16.4 (17.7)	27.2 (19.9)	0.035	1.047	0.983–1.115	0.15
Number of IVR	2.9 (2.8)	2.9 (1.6)	0.44
Hypertension, +/−	4/5	10/8	0.44
Diabetes, +/−	1/8	3/15	0.59
CMT, µm	442.7 (120.7)	546.2 (158.2)	0.09
CME, +/−	6/3	11/7	0.56
SRF, +/−	0/9	5/13	0.11
ERM, +/−	2/7	3/15	0.55

Note: Younger age was associated with a good BCVA at 1 month postinjection in the switching group.

Abbreviations: logMAR, logarithm of the minimum angle of resolution; CI, confidence interval; SD, standard deviation; IVR, intravitreal ranibizumab; CMT, central macular thickness; CME, cystoid macular edema; SRF, subretinal fluid; ERM, epiretinal membrane; BCVA, best-corrected visual acuity.

Table 3 Preswitching parameters associated with CMT at 1 month post-IVA

CMT at 1 month post-IVA	<300 µm	≥300 µm	P-value
Age, mean (SD), years	71.4 (8.9)	75.5 (3.7)	0.34
Sex, male/female	9/14	1/3	0.52
Duration from onset	20.7 (17.9)	40.3 (23.0)	0.07
Number of IVR	2.8 (2.9)	3.3 (2.1)	0.62
Hypertension, +/−	12/11	2/2	0.67
Diabetes, +/−	3/20	1/3	0.50
CMT, µm	498.8 (493.6)	585.8 (177.6)	0.31
CME, +/−	3/20	2/2	0.48
SRF, +/−	4/19	1/3	0.58
ERM, +/−	2/21	3/1	0.01

Note: Absence of the epiretinal membrane was associated with improvement of the CMT at 1 month postinjection in the switching group.

Abbreviations: IVA, intravitreal aflibercept; SD, standard deviation; IVR, intravitreal ranibizumab; CMT, central macular thickness; CME, cystoid macular edema; SRF, subretinal fluid; ERM, epiretinal membrane.